Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Roth Capital maintains Buy on RedHill after 'noisy' quarter » 07:36
08/14/20
08/14
07:36
08/14/20
07:36
RDHL

RedHill Biopharma

$8.37 /

-0.81 (-8.82%)

Roth Capital analyst…

Roth Capital analyst Scott Henry maintained a Buy rating and $16 price target on RedHill Biopharma following a "noisy" Q2 report that was "fundamentally within expectations." He added that COVID-19 data in Q4, possibly as soon as September, could be a catalyst for the stock going forward.

ShowHide Related Items >><<
RDHL RedHill Biopharma
$8.37 /

-0.81 (-8.82%)

RDHL RedHill Biopharma
$8.37 /

-0.81 (-8.82%)

07/07/20 SMBC Nikko
RedHill Biopharma initiated with an Outperform at SMBC Nikko
02/27/20 Roth Capital
RedHill Biopharma price target lowered to $15 from $20.25 at Roth Capital
RDHL RedHill Biopharma
$8.37 /

-0.81 (-8.82%)

RDHL RedHill Biopharma
$8.37 /

-0.81 (-8.82%)

Thursday
On The Fly
Fly Intel: Pre-market Movers » 09:00
08/13/20
08/13
09:00
08/13/20
09:00
AAPL

Apple

$452.23 /

+14.535 (+3.32%)

, PENN

Penn National

$49.75 /

+3.22 (+6.92%)

, BCRX

BioCryst

$3.99 /

+0.045 (+1.14%)

, TPR

Tapestry

$15.57 /

+0.03 (+0.19%)

, RDHL

RedHill Biopharma

$9.18 /

+0.21 (+2.34%)

, GRWG

GrowGeneration

$8.76 /

+0.16 (+1.86%)

, MGIC

Magic Software

$13.27 /

+0.06 (+0.45%)

, DSSI

Diamond S Shipping

$8.65 /

+0.265 (+3.16%)

, VBLT

VBL Therapeutics

$1.31 /

+ (+0.00%)

, VRM

Vroom

$69.34 /

+4.45 (+6.86%)

, CSCO

Cisco

$48.08 /

+0.86 (+1.82%)

, PTON

Peloton

$64.30 /

-0.63 (-0.97%)

, STC

Stewart

$40.94 /

-2.415 (-5.57%)

, IVZ

Invesco

$11.24 /

+0.44 (+4.08%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
VRM Vroom
$69.34 /

+4.45 (+6.86%)

VBLT VBL Therapeutics
$1.31 /

+ (+0.00%)

TPR Tapestry
$15.57 /

+0.03 (+0.19%)

STC Stewart
$40.94 /

-2.415 (-5.57%)

RDHL RedHill Biopharma
$9.18 /

+0.21 (+2.34%)

PTON Peloton
$64.30 /

-0.63 (-0.97%)

PENN Penn National
$49.75 /

+3.22 (+6.92%)

IVZ Invesco
$11.24 /

+0.44 (+4.08%)

GRWG GrowGeneration
$8.76 /

+0.16 (+1.86%)

DSSI Diamond S Shipping
$8.65 /

+0.265 (+3.16%)

CSCO Cisco
$48.08 /

+0.86 (+1.82%)

BCRX BioCryst
$3.99 /

+0.045 (+1.14%)

AAPL Apple
$452.23 /

+14.535 (+3.32%)

AAPL Apple
$452.23 /

+14.535 (+3.32%)

08/12/20 Wedbush
Tesla stock split 'a smart strategic move,' says Wedbush
08/11/20 Evercore ISI
Apple underperformance influenced by China smartphone data, says Evercore ISI
08/10/20 Deutsche Bank
Apple price target raised to $480 from $440 at Deutsche Bank
08/10/20 Wedbush
Apple price target raised to $515 from $475 at Wedbush
PENN Penn National
$49.75 /

+3.22 (+6.92%)

08/13/20 Goldman Sachs
Penn National initiated with a Buy at Goldman Sachs
08/07/20 Barclays
Penn National price target raised to $50 from $42 at Barclays
07/30/20 Morgan Stanley
Sports betting unlikely to get legalized in MA this week, says Morgan Stanley
07/29/20 Jefferies
MA Bill H4887 a positive for DraftKings, Penn National, says Jefferies
BCRX BioCryst
$3.99 /

+0.045 (+1.14%)

06/26/20 JMP Securities
BioCryst price target raised to $11 from $10 at JMP Securities
06/16/20 BTIG
BioCryst initiated with a Neutral at BTIG
05/06/20 JMP Securities
BioCryst has potential best-in-class PNH treatment, says JMP Securities
05/06/20 Piper Sandler
BioCryst price target raised to $10 from $8 at Piper Sandler
TPR Tapestry
$15.57 /

+0.03 (+0.19%)

07/27/20
Fly Intel: Top five analyst upgrades
07/27/20 Goldman Sachs
Tapestry upgraded to Buy from Neutral at Goldman Sachs
05/07/20
Fly Intel: Top five analyst upgrades
05/07/20 HSBC
Tapestry upgraded to Buy from Hold at HSBC
RDHL RedHill Biopharma
$9.18 /

+0.21 (+2.34%)

07/07/20 SMBC Nikko
RedHill Biopharma initiated with an Outperform at SMBC Nikko
02/27/20 Roth Capital
RedHill Biopharma price target lowered to $15 from $20.25 at Roth Capital
GRWG GrowGeneration
$8.76 /

+0.16 (+1.86%)

07/17/20 Lake Street
GrowGeneration price target raised to $9 from $7 at Lake Street
07/14/20 Oppenheimer
Oppenheimer bullish on GrowGeneration, initiates with an Outperform
07/14/20 Oppenheimer
GrowGeneration initiated with an Outperform at Oppenheimer
07/08/20 Alliance Global Partners
GrowGeneration price target raised to $10 from $8 at Alliance Global Partners
MGIC Magic Software
$13.27 /

+0.06 (+0.45%)

03/26/20 MKM Partners
MKM Partners sees Mortgage Insurers as attractively valued
03/11/20
Fly Intel: Top five analyst downgrades
03/11/20 H.C. Wainwright
Magic Software downgraded to Neutral from Buy at H.C. Wainwright
11/15/19 H.C. Wainwright
Magic Software price target raised to $11 from $10 at H.C. Wainwright
DSSI Diamond S Shipping
$8.65 /

+0.265 (+3.16%)

07/15/20 B. Riley FBR
Diamond S Shipping price target lowered to $21 from $25 at B. Riley FBR
03/30/20 Fearnley
Diamond S Shipping downgraded to Hold from Buy at Fearnley
01/08/20 B. Riley FBR
B. Riley FBR sees another strong year for tanker stocks in 2020
10/10/19 Jefferies
Diamond S Shipping initiated with a Buy rating at Jefferies
VBLT VBL Therapeutics
$1.31 /

+ (+0.00%)

11/14/19 Chardan
VBL Therapeutics upgraded to Buy with $3.25 price target at Chardan
11/14/19 Chardan
VBL Therapeutics upgraded to Buy from Neutral at Chardan
VRM Vroom
$69.34 /

+4.45 (+6.86%)

08/13/20 Wells Fargo
Vroom price target raised to $76 from $65 at Wells Fargo
08/13/20 Wedbush
Vroom price target raised to $80 from $75 at Wedbush
08/13/20 Baird
Baird would be buyers of Vroom amid post-earnings weakness
08/06/20 Wedbush
Carvana price target raised to $170 from $125 at Wedbush
CSCO Cisco
$48.08 /

+0.86 (+1.82%)

08/13/20 JPMorgan
Cisco price target lowered to $46 from $50 at JPMorgan
08/13/20 Barclays
Cisco guidance raises concerns about 'relative resilience,' says Barclays
08/13/20 Morgan Stanley
Cisco valuation likely to lag until more clarity, says Morgan Stanley
08/13/20 RBC Capital
Cisco results in line, but outlook disappoints, says RBC Capital
PTON Peloton
$64.30 /

-0.63 (-0.97%)

08/11/20 Rosenblatt
Nautilus' strong trends a positive for Peloton, says Rosenblatt
07/20/20 Goldman Sachs
Peloton price target raised to $84 from $66 at Goldman Sachs
07/16/20
Fly Intel: Top five analyst downgrades
07/16/20 Barclays
Peloton price target raised to $74 from $50 at Barclays
STC Stewart
$40.94 /

-2.415 (-5.57%)

07/27/20 Keefe Bruyette
Stewart upgraded to Outperform from Market Perform at Keefe Bruyette
04/20/20 Stephens
Stephens ups CoreLogic, downgrades two others in real estate services shake-up
04/08/20 Keefe Bruyette
Stewart upgraded to Market Perform from Underperform at Keefe Bruyette
IVZ Invesco
$11.24 /

+0.44 (+4.08%)

08/13/20 Barclays
Invesco downgraded to Underweight from Equal Weight at Barclays
04/24/20 Citi
Invesco price target lowered to $4.50 from $5.50 at Citi
04/23/20 Keefe Bruyette
Invesco downgraded to Market Perform from Outperform at Keefe Bruyette
04/15/20 Citi
Invesco downgraded to Sell from Neutral at Citi
VRM Vroom
$69.34 /

+4.45 (+6.86%)

VBLT VBL Therapeutics
$1.31 /

+ (+0.00%)

TPR Tapestry
$15.57 /

+0.03 (+0.19%)

STC Stewart
$40.94 /

-2.415 (-5.57%)

RDHL RedHill Biopharma
$9.18 /

+0.21 (+2.34%)

PTON Peloton
$64.30 /

-0.63 (-0.97%)

PENN Penn National
$49.75 /

+3.22 (+6.92%)

MGIC Magic Software
$13.27 /

+0.06 (+0.45%)

IVZ Invesco
$11.24 /

+0.44 (+4.08%)

GRWG GrowGeneration
$8.76 /

+0.16 (+1.86%)

DSSI Diamond S Shipping
$8.65 /

+0.265 (+3.16%)

CSCO Cisco
$48.08 /

+0.86 (+1.82%)

BCRX BioCryst
$3.99 /

+0.045 (+1.14%)

AAPL Apple
$452.23 /

+14.535 (+3.32%)

  • 13
    Aug
  • 30
    Jun
  • 09
    Jun
  • 28
    May
  • 12
    May
  • 21
    Nov
  • 14
    Nov
  • 26
    Sep
TPR Tapestry
$15.57 /

+0.03 (+0.19%)

PTON Peloton
$64.30 /

-0.63 (-0.97%)

PENN Penn National
$49.75 /

+3.22 (+6.92%)

IVZ Invesco
$11.24 /

+0.44 (+4.08%)

CSCO Cisco
$48.08 /

+0.86 (+1.82%)

AAPL Apple
$452.23 /

+14.535 (+3.32%)

VRM Vroom
$69.34 /

+4.45 (+6.86%)

TPR Tapestry
$15.57 /

+0.03 (+0.19%)

PTON Peloton
$64.30 /

-0.63 (-0.97%)

PENN Penn National
$49.75 /

+3.22 (+6.92%)

MGIC Magic Software
$13.27 /

+0.06 (+0.45%)

IVZ Invesco
$11.24 /

+0.44 (+4.08%)

GRWG GrowGeneration
$8.76 /

+0.16 (+1.86%)

CSCO Cisco
$48.08 /

+0.86 (+1.82%)

BCRX BioCryst
$3.99 /

+0.045 (+1.14%)

AAPL Apple
$452.23 /

+14.535 (+3.32%)

VRM Vroom
$69.34 /

+4.45 (+6.86%)

TPR Tapestry
$15.57 /

+0.03 (+0.19%)

PTON Peloton
$64.30 /

-0.63 (-0.97%)

PENN Penn National
$49.75 /

+3.22 (+6.92%)

IVZ Invesco
$11.24 /

+0.44 (+4.08%)

GRWG GrowGeneration
$8.76 /

+0.16 (+1.86%)

CSCO Cisco
$48.08 /

+0.86 (+1.82%)

BCRX BioCryst
$3.99 /

+0.045 (+1.14%)

AAPL Apple
$452.23 /

+14.535 (+3.32%)

AAPL Apple
$452.23 /

+14.535 (+3.32%)

Earnings
RedHill Biopharma reports Q2 EPS (4c), consenus (7c) » 07:16
08/13/20
08/13
07:16
08/13/20
07:16
RDHL

RedHill Biopharma

$9.18 /

+0.21 (+2.34%)

Reports Q2 revenue $21M,…

Reports Q2 revenue $21M, consensus $22.99M. Dror Ben-Asher, RedHill's Chief Executive Officer, said: "This has been a standout period for RedHill with the acquisition of Movantik from AstraZeneca and the launch of Talicia. From an R&D perspective, we have been making progress against some of the world's most pressing healthcare challenges - COVID-19, infectious diseases and antibiotic resistance. We have worked diligently and rapidly to initiate in parallel global Phase 2/3 and U.S. Phase 2 studies, with potential global emergency use applications expected as early as the fourth quarter of this year. We are also making the necessary preparations to make opaganib widely available, subject to positive results from the two ongoing studies and potential global emergency use authorizations, if granted. We are also delighted with the recent FDA clearance to initiate the pivotal Phase 3 study with RHB-204 in first-line pulmonary NTM infections, a rare and highly resistant infectious disease with no FDA-approved first-line therapy. In summary, with three FDA-approved products being promoted, commercial operations largely resumed, growing revenues, and our late-stage development programs progressing as planned, we are well-positioned for continued and rapid growth, with a number of near- and long-term growth drivers."

ShowHide Related Items >><<
RDHL RedHill Biopharma
$9.18 /

+0.21 (+2.34%)

RDHL RedHill Biopharma
$9.18 /

+0.21 (+2.34%)

07/07/20 SMBC Nikko
RedHill Biopharma initiated with an Outperform at SMBC Nikko
02/27/20 Roth Capital
RedHill Biopharma price target lowered to $15 from $20.25 at Roth Capital
RDHL RedHill Biopharma
$9.18 /

+0.21 (+2.34%)

Hot Stocks
RedHill Biopharma and Cosmo Pharma sign licensing and manufacturing agreement » 06:13
08/13/20
08/13
06:13
08/13/20
06:13
RDHL

RedHill Biopharma

$9.18 /

+0.21 (+2.34%)

RedHill Biopharma has…

RedHill Biopharma has entered into a binding term sheet with Cosmo Pharmaceuticals for an exclusive licensing and manufacturing agreement for multiple products. The transaction is expected to close in the coming weeks. The companies will co-develop a novel next-generation therapy for the eradication of H. pylori infection. Cosmo is to receive the exclusive European rights to the new drug and will pay RedHill $7M upon signing of the license agreement and an additional $2M upon approval in Europe, and 30% royalties. The companies plan to jointly execute clinical trials pursuing simultaneous regulatory approvals in the U.S. and Europe, with a cost split 70% RedHill and 30% Cosmo. Cosmo will become the exclusive worldwide manufacturer for the novel next-generation therapy for the eradication of H. pylori infection, Movantik, which RedHill recently acquired from AstraZeneca, and RHB-204 for pulmonary nontuberculous mycobacteria infections. Cosmo will be paid EUR5.5M for tech transfer, formulation and development work with respect of these products. Additionally, Cosmo will finance the planned pivotal Phase 3 clinical study with RHB-204, which recently received FDA clearance to proceed, with a payment of $5M upon signing of the agreement and an additional $7M in two milestone payments. Cosmo will be entitled to 15% royalty payments.

ShowHide Related Items >><<
RDHL RedHill Biopharma
$9.18 /

+0.21 (+2.34%)

RDHL RedHill Biopharma
$9.18 /

+0.21 (+2.34%)

07/07/20 SMBC Nikko
RedHill Biopharma initiated with an Outperform at SMBC Nikko
02/27/20 Roth Capital
RedHill Biopharma price target lowered to $15 from $20.25 at Roth Capital
RDHL RedHill Biopharma
$9.18 /

+0.21 (+2.34%)

Wednesday
Conference/Events
CFA Society of Minnesota to hold a virtual conference » 09:06
08/12/20
08/12
09:06
08/12/20
09:06
GIS

General Mills

$62.14 /

-1.61 (-2.53%)

, GGG

Graco

$57.40 /

+2.415 (+4.39%)

, CLXT

Calyxt

$6.99 /

+0.57 (+8.88%)

, ASB

Associated Banc-Corp

$14.26 /

+0.25 (+1.78%)

, APG

APi Group

$14.71 /

-0.02 (-0.14%)

, APAM

Artisan Partners

$38.84 /

-0.035 (-0.09%)

, NVEC

NVE Corp.

$56.07 /

+0.03 (+0.05%)

, RDHL

RedHill Biopharma

$8.97 /

-0.8 (-8.19%)

, IIN

IntriCon

$12.69 /

+1.31 (+11.51%)

, MOS

Mosaic

$17.63 /

-0.775 (-4.21%)

, TECH

Bio-Techne

$261.68 /

+3.68 (+1.43%)

, TCF

TCF Financial

$29.31 /

+0.91 (+3.20%)

, PNR

Pentair

$44.86 /

+0.34 (+0.76%)

, VSTO

Vista Outdoor

$20.35 /

-1.86 (-8.37%)

, XEL

Xcel Energy

$70.53 /

-1.93 (-2.66%)

, EBS

Emergent BioSolutions

$122.47 /

-7.53 (-5.79%)

, BKH

Black Hills

$58.82 /

-1.09 (-1.82%)

, CF

CF Industries

$35.51 /

+0.625 (+1.79%)

Intellisight 2020 Virtual…

Intellisight 2020 Virtual Conference will be held on August 12. Webcast Link

ShowHide Related Items >><<
XEL Xcel Energy
$70.53 /

-1.93 (-2.66%)

VSTO Vista Outdoor
$20.35 /

-1.86 (-8.37%)

TECH Bio-Techne
$261.68 /

+3.68 (+1.43%)

TCF TCF Financial
$29.31 /

+0.91 (+3.20%)

RDHL RedHill Biopharma
$8.97 /

-0.8 (-8.19%)

PNR Pentair
$44.86 /

+0.34 (+0.76%)

MOS Mosaic
$17.63 /

-0.775 (-4.21%)

IIN IntriCon
$12.69 /

+1.31 (+11.51%)

GIS General Mills
$62.14 /

-1.61 (-2.53%)

GGG Graco
$57.40 /

+2.415 (+4.39%)

EBS Emergent BioSolutions
$122.47 /

-7.53 (-5.79%)

CLXT Calyxt
$6.99 /

+0.57 (+8.88%)

CF CF Industries
$35.51 /

+0.625 (+1.79%)

BKH Black Hills
$58.82 /

-1.09 (-1.82%)

ASB Associated Banc-Corp
$14.26 /

+0.25 (+1.78%)

APG APi Group
$14.71 /

-0.02 (-0.14%)

APAM Artisan Partners
$38.84 /

-0.035 (-0.09%)

GIS General Mills
$62.14 /

-1.61 (-2.53%)

07/15/20 Guggenheim
General Mills price target raised to $72 from $66 at Guggenheim
07/02/20 BMO Capital
General Mills price target raised to $66 from $63 at BMO Capital
06/29/20 Jefferies
Jefferies staying sidelined on General Mills ahead of earnings
06/11/20 Bernstein
General Mills downgraded to Underperform from Market Perform at Bernstein
GGG Graco
$57.40 /

+2.415 (+4.39%)

08/11/20
Fly Intel: Top five analyst upgrades
08/11/20 RBC Capital
Graco upgraded to Outperform from Sector Perform at RBC Capital
07/23/20 Baird
Graco price target raised to $65 from $58 at Baird
07/14/20 Baird
Graco upgraded to Outperform from Neutral at Baird
CLXT Calyxt
$6.99 /

+0.57 (+8.88%)

07/28/20 Canaccord
Canaccord starts Calyxt with Buy rating, $8 price target
07/28/20 Canaccord
Calyxt initiated with a Buy at Canaccord
05/08/20 BMO Capital
Calyxt downgraded to Market Perform from Outperform at BMO Capital
03/23/20 Jefferies
Jefferies downgrades 10 'lower conviction' Chemicals stocks to Hold
ASB Associated Banc-Corp
$14.26 /

+0.25 (+1.78%)

07/09/20 Jefferies
Associated Banc-Corp downgraded to Hold from Buy at Jefferies
03/30/20 Wells Fargo
Associated Banc-Corp upgraded to Equal Weight from Underweight at Wells Fargo
03/30/20 Wells Fargo
Associated Banc-Corp upgraded to Equal Weight from Underweight at Wells Fargo
03/06/20 Truist
SunTrust cuts price targets on Banks amid lower interest rate environment
APG APi Group
$14.71 /

-0.02 (-0.14%)

06/24/20 Baird
APi Group initiated with an Outperform at Baird
06/23/20 Baird
APi Group initiated with an Outperform at Baird
06/03/20 Citi
APi Group price target raised to $14 from $12 at Citi
05/27/20 UBS
APi Group initiated with a Buy at UBS
APAM Artisan Partners
$38.84 /

-0.035 (-0.09%)

07/31/20 Goldman Sachs
Artisan Partners upgraded to Buy from Sell at Goldman Sachs
04/30/20
Fly Intel: Top five analyst upgrades
04/30/20 Keefe Bruyette
Artisan Partners upgraded to Outperform from Market Perform at Keefe Bruyette
03/26/20 BofA
BofA double upgrades Artisan Partners, Federated to Buy after selloff
NVEC NVE Corp.
$56.07 /

+0.03 (+0.05%)

RDHL RedHill Biopharma
$8.97 /

-0.8 (-8.19%)

07/07/20 SMBC Nikko
RedHill Biopharma initiated with an Outperform at SMBC Nikko
02/27/20 Roth Capital
RedHill Biopharma price target lowered to $15 from $20.25 at Roth Capital
IIN IntriCon
$12.69 /

+1.31 (+11.51%)

05/20/20 B. Riley FBR
IntriCon price target raised to $28 from $26.50 at B. Riley FBR
01/08/20 B. Riley FBR
B. Riley FBR highlights six Specialty Pharma stocks for 2020
09/20/19
IntriCon initiated with a Buy at Dougherty
MOS Mosaic
$17.63 /

-0.775 (-4.21%)

08/10/20 Goldman Sachs
Mosaic price target raised to $17 from $14 at Goldman Sachs
07/15/20 Citi
Mosaic upgraded to Buy from Neutral at Citi
06/29/20
Fly Intel: Top five analyst upgrades
06/29/20 BofA
Mosaic upgraded to Buy from Underperform at BofA
TECH Bio-Techne
$261.68 /

+3.68 (+1.43%)

08/05/20 SVB Leerink
Bio-Techne price target raised to $285 from $265 at SVB Leerink
08/04/20 Craig-Hallum
Craig-Hallum upgrades Bio-Techne on 'powerful, long-term trend'
08/04/20 Craig-Hallum
Bio-Techne upgraded to Buy from Hold at Craig-Hallum
07/15/20 Stephens
Bio-Techne downgraded to Equal Weight from Overweight at Stephens
TCF TCF Financial
$29.31 /

+0.91 (+3.20%)

06/08/20 BofA
TCF Financial upgraded to Buy from Neutral at BofA
06/08/20 BofA
TCF Financial upgraded to Buy from Neutral at BofA
04/17/20 Wedbush
TCF Financial upgraded to Outperform from Neutral at Wedbush
04/17/20 Wedbush
TCF Financial upgraded to Outperform from Neutral at Wedbush
PNR Pentair
$44.86 /

+0.34 (+0.76%)

07/24/20 RBC Capital
Pentair price target raised to $44 from $39 at RBC Capital
07/09/20 BofA
Pentair double-upgraded to Buy from Underperform at BofA
07/09/20 BofA
Pentair upgraded to Buy from Underperform at BofA
05/15/20 Vertical Research
Pentair upgraded to Buy from Hold at Vertical Research
VSTO Vista Outdoor
$20.35 /

-1.86 (-8.37%)

07/08/20
Fly Intel: Top five analyst downgrades
07/08/20 B. Riley FBR
Vista Outdoor downgraded to Neutral after 115% rally at B. Riley FBR
07/08/20 B. Riley FBR
Vista Outdoor downgraded to Neutral from Buy at B. Riley FBR
07/07/20 Lake Street
Vista Outdoor price target raised to $18 from $13 at Lake Street
XEL Xcel Energy
$70.53 /

-1.93 (-2.66%)

05/13/20 Morgan Stanley
Xcel Energy downgraded to Underweight following outperformance at Morgan Stanley
05/13/20 Morgan Stanley
Xcel Energy downgraded to Underweight from Equal Weight at Morgan Stanley
04/24/20 Morgan Stanley
Federal support for renewables could come in summer, says Morgan Stanley
04/24/20 Wells Fargo
Xcel Energy downgraded to Equal Weight at Wells Fargo on relative valuation
EBS Emergent BioSolutions
$122.47 /

-7.53 (-5.79%)

07/17/20 Cantor Fitzgerald
Emergent BioSolutions price target raised to $110 from $85 at Cantor Fitzgerald
07/02/20 Wells Fargo
Emergent BioSolutions price target raised to $93 from $85 at Wells Fargo
06/26/20 Raymond James
Vaxart already had vaccine deals with Emergent, Kindred, notes Raymond James
06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
BKH Black Hills
$58.82 /

-1.09 (-1.82%)

07/02/20 Mizuho
Black Hills price target lowered to $70 from $77 at Mizuho
05/22/20 Mizuho
Black Hills price target raised to $71 from $66 at Mizuho
05/21/20 Sidoti
Black Hills upgraded to Buy following pullback at Sidoti
05/21/20 Sidoti
Black Hills upgraded to Buy from Neutral at Sidoti
CF CF Industries
$35.51 /

+0.625 (+1.79%)

08/10/20 Citi
CF Industries upgraded to Buy from Neutral at Citi
08/07/20
Fly Intel: Top five analyst upgrades
08/07/20 Citi
CF Industries upgraded to Buy from Neutral at Citi
08/07/20 Citi
CF Industries upgraded to Buy from Neutral at Citi
XEL Xcel Energy
$70.53 /

-1.93 (-2.66%)

VSTO Vista Outdoor
$20.35 /

-1.86 (-8.37%)

TECH Bio-Techne
$261.68 /

+3.68 (+1.43%)

TCF TCF Financial
$29.31 /

+0.91 (+3.20%)

RDHL RedHill Biopharma
$8.97 /

-0.8 (-8.19%)

PNR Pentair
$44.86 /

+0.34 (+0.76%)

MOS Mosaic
$17.63 /

-0.775 (-4.21%)

IIN IntriCon
$12.69 /

+1.31 (+11.51%)

GIS General Mills
$62.14 /

-1.61 (-2.53%)

GGG Graco
$57.40 /

+2.415 (+4.39%)

EBS Emergent BioSolutions
$122.47 /

-7.53 (-5.79%)

CLXT Calyxt
$6.99 /

+0.57 (+8.88%)

CF CF Industries
$35.51 /

+0.625 (+1.79%)

BKH Black Hills
$58.82 /

-1.09 (-1.82%)

ASB Associated Banc-Corp
$14.26 /

+0.25 (+1.78%)

APAM Artisan Partners
$38.84 /

-0.035 (-0.09%)

  • 20
    Feb
  • 31
    Oct
VSTO Vista Outdoor
$20.35 /

-1.86 (-8.37%)

TCF TCF Financial
$29.31 /

+0.91 (+3.20%)

GIS General Mills
$62.14 /

-1.61 (-2.53%)

VSTO Vista Outdoor
$20.35 /

-1.86 (-8.37%)

TCF TCF Financial
$29.31 /

+0.91 (+3.20%)

MOS Mosaic
$17.63 /

-0.775 (-4.21%)

IIN IntriCon
$12.69 /

+1.31 (+11.51%)

GIS General Mills
$62.14 /

-1.61 (-2.53%)

EBS Emergent BioSolutions
$122.47 /

-7.53 (-5.79%)

CF CF Industries
$35.51 /

+0.625 (+1.79%)

PNR Pentair
$44.86 /

+0.34 (+0.76%)

MOS Mosaic
$17.63 /

-0.775 (-4.21%)

GIS General Mills
$62.14 /

-1.61 (-2.53%)

CF CF Industries
$35.51 /

+0.625 (+1.79%)

APG APi Group
$14.71 /

-0.02 (-0.14%)

Over a week ago
Hot Stocks
RedHill Biopharma Phase 2/3 COVID-19 study approved in Mexico » 08:05
08/06/20
08/06
08:05
08/06/20
08:05
RDHL

RedHill Biopharma

$7.52 /

+0.145 (+1.97%)

RedHill Biopharma…

RedHill Biopharma announced approval from the Mexican Federal Committee for the Protection against Sanitary Risks for the Company's Clinical Trial Authorization application for the Phase 2/3 study evaluating opaganib in patients hospitalized with severe SARS-CoV-2 infection and pneumonia. RedHill's study has now been approved in Mexico, the UK, and Russia and is under review in Italy, Brazil and additional countries. Further expansion of the study to other countries is planned. The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 study is set to enroll up to 270 patients with severe COVID-19 pneumonia requiring hospitalization and treatment with supplemental oxygen. Subjects will be randomized at a 1:1 ratio to receive either opaganib or placebo, along with standard-of-care therapy. The primary endpoint of the study is to evaluate the proportion of patients requiring intubation and mechanical ventilation by Day 14. An unblinded futility interim analysis will be conducted by an independent data safety monitoring board when approximately 100 subjects have been evaluated for the primary endpoint. In parallel, enrollment in the U.S. Phase 2 clinical study with opaganib is approximately 50% complete and is expected to be completed this month. This randomized, double-blind, placebo-controlled study, which is not powered for statistical significance, is set to enroll up to 40 patients with severe COVID-19 pneumonia requiring hospitalization and supplemental oxygen.

ShowHide Related Items >><<
RDHL RedHill Biopharma
$7.52 /

+0.145 (+1.97%)

RDHL RedHill Biopharma
$7.52 /

+0.145 (+1.97%)

07/07/20 SMBC Nikko
RedHill Biopharma initiated with an Outperform at SMBC Nikko
02/27/20 Roth Capital
RedHill Biopharma price target lowered to $15 from $20.25 at Roth Capital
RDHL RedHill Biopharma
$7.52 /

+0.145 (+1.97%)

Hot Stocks
RedHill Biopharma announces agreement with Daiichi Sankyo for Movantik » 07:18
08/03/20
08/03
07:18
08/03/20
07:18
RDHL

RedHill Biopharma

$7.90 /

+0.35 (+4.64%)

, DSNKY

Daiichi Sankyo

$0.00 /

+ (+0.00%)

RedHill Biopharma (RDHL)…

RedHill Biopharma (RDHL) announced that it has replaced its existing 2015 co-commercialization agreement with Daiichi Sankyo (DSNKY) for Movantik, which was assigned to RedHill under its April 2020 acquisition agreement with AstraZeneca, with a new royalty-bearing agreement. Under the terms of the new agreement, RedHill will bear all responsibilities and costs for commercializing Movantik in the U.S. During the term of this new agreement, RedHill will pay Daiichi Sankyo a mid-teen royalty rate on net sales of Movantik in the U.S., in addition to three lump sum payments each year starting in 2021 and ending in 2023. In addition, the companies also entered a subscription agreement under which Daiichi Sankyo received 283,387 in American Depositary Shares of RedHill as a partial consideration in relation to Movantik. RedHill acquired the global rights, excluding Europe, Canada and Israel, to Movantik for the treatment of opioid induced constipation from AstraZeneca in April 2020 and immediately initiated promotion in the U.S. with its expanded sales force.

ShowHide Related Items >><<
RDHL RedHill Biopharma
$7.90 /

+0.35 (+4.64%)

DSNKY Daiichi Sankyo
$0.00 /

+ (+0.00%)

RDHL RedHill Biopharma
$7.90 /

+0.35 (+4.64%)

07/07/20 SMBC Nikko
RedHill Biopharma initiated with an Outperform at SMBC Nikko
02/27/20 Roth Capital
RedHill Biopharma price target lowered to $15 from $20.25 at Roth Capital
DSNKY Daiichi Sankyo
$0.00 /

+ (+0.00%)

06/08/20 Jefferies
Jefferies downgrades Daiichi Sankyo to Hold with Enhertu seen as priced in
06/08/20 Jefferies
Daiichi Sankyo downgraded to Hold from Buy at Jefferies
12/09/19 Jefferies
Daiichi Sankyo initiated with a Buy at Jefferies
RDHL RedHill Biopharma
$7.90 /

+0.35 (+4.64%)

Hot Stocks
RedHill gets FDA clearance for Phase 3 study with RHB-204 for NTM infections » 07:05
07/31/20
07/31
07:05
07/31/20
07:05
RDHL

RedHill Biopharma

$7.55 /

+0.74 (+10.87%)

RedHill Biopharma…

RedHill Biopharma announced that the U.S. Food and Drug Administration, FDA, has cleared its Investigational New Drug application for a pivotal Phase 3 study to evaluate the efficacy and safety of RHB-204 in adults with pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex, MAC, infection. Kevin L. Winthrop, MD, M.P.H., Professor of Infectious Diseases and Public Health at the Oregon Health & Science University - Portland State University (OHSU-PSU) School of Public Health and Principal Investigator of the study, said: "NTM infections are enormously challenging, resistant to most antibiotics, and can cause significant lung damage - and they are becoming more prevalent. There is a tremendous unmet need with regard to FDA-approved therapies for NTM, and both physicians and patients need additional treatment options." Gilead Raday, RedHill's Chief Operating Officer, added: "There is currently no FDA-approved first-line, standard-of-care therapy for patients suffering from pulmonary NTM infections. We are looking forward to completing our discussions with FDA and initiating this pivotal study at leading clinical sites across the U.S., evaluating RHB-204 as a first-line, stand-alone, orally-administered therapy."

ShowHide Related Items >><<
RDHL RedHill Biopharma
$7.55 /

+0.74 (+10.87%)

RDHL RedHill Biopharma
$7.55 /

+0.74 (+10.87%)

07/07/20 SMBC Nikko
RedHill Biopharma initiated with an Outperform at SMBC Nikko
02/27/20 Roth Capital
RedHill Biopharma price target lowered to $15 from $20.25 at Roth Capital
RDHL RedHill Biopharma
$7.55 /

+0.74 (+10.87%)

Hot Stocks
RedHill Biopharma initiates global Phase 2/3 study for COVID-19 » 07:57
07/30/20
07/30
07:57
07/30/20
07:57
RDHL

RedHill Biopharma

$6.81 /

+0.13 (+1.95%)

RedHill Biopharma…

RedHill Biopharma announced that it has initiated a global Phase 2/3 clinical study evaluating opaganib in patients hospitalized with severe SARS-CoV-2 infection and pneumonia requiring treatment with supplemental oxygen. The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 study is set to enroll up to 270 patients in up to 40 clinical sites across European, Latin American and other countries. Further expansion of the study to additional countries is planned. Subjects enrolled in the study will be randomized at a 1:1 ratio to receive either opaganib or placebo, along with standard-of-care therapy. The primary endpoint of the study is to evaluate the proportion of patients requiring intubation and mechanical ventilation by Day 14. An unblinded futility interim analysis will be conducted by an independent data safety monitoring board when approximately 100 subjects have been evaluated for the primary endpoint. Enrollment is also ongoing for a randomized, double-blind, placebo-controlled Phase 2 clinical study with opaganib in the U.S. This study is set to enroll up to 40 patients with severe COVID-19 pneumonia requiring hospitalization and supplemental oxygen, with enrollment expected to be completed in August. This clinical trial is not powered for statistical significance.

ShowHide Related Items >><<
RDHL RedHill Biopharma
$6.81 /

+0.13 (+1.95%)

RDHL RedHill Biopharma
$6.81 /

+0.13 (+1.95%)

07/07/20 SMBC Nikko
RedHill Biopharma initiated with an Outperform at SMBC Nikko
02/27/20 Roth Capital
RedHill Biopharma price target lowered to $15 from $20.25 at Roth Capital
RDHL RedHill Biopharma
$6.81 /

+0.13 (+1.95%)

Hot Stocks
RedHill increases patient access to Talicia with EnvisionRx Formularies » 07:23
07/27/20
07/27
07:23
07/27/20
07:23
RDHL

RedHill Biopharma

$6.89 /

+0.34 (+5.19%)

, RAD

Rite Aid

$15.11 /

-0.45 (-2.89%)

RedHill Biopharma (RDHL)…

RedHill Biopharma (RDHL) announced that EnvisionRx, a Pharmacy Benefit Manager and division of EnvisionRxOptions, a wholly owned subsidiary of Rite Aid (RAD), added Talicia to its Formularies, as the unrestricted branded agent for H. pylori treatment, effective July 1, 2020.

ShowHide Related Items >><<
RDHL RedHill Biopharma
$6.89 /

+0.34 (+5.19%)

RAD Rite Aid
$15.11 /

-0.45 (-2.89%)

RDHL RedHill Biopharma
$6.89 /

+0.34 (+5.19%)

07/07/20 SMBC Nikko
RedHill Biopharma initiated with an Outperform at SMBC Nikko
02/27/20 Roth Capital
RedHill Biopharma price target lowered to $15 from $20.25 at Roth Capital
RAD Rite Aid
$15.11 /

-0.45 (-2.89%)

06/26/20 JPMorgan
Rite Aid price target raised to $17 from $12 at JPMorgan
06/26/20 Deutsche Bank
Rite Aid price target raised to $18 from $12 at Deutsche Bank
04/17/20
Fly Intel: Top five analyst upgrades
04/17/20 Deutsche Bank
Rite Aid upgraded to Hold from Sell at Deutsche Bank
RDHL RedHill Biopharma
$6.89 /

+0.34 (+5.19%)

RAD Rite Aid
$15.11 /

-0.45 (-2.89%)

RAD Rite Aid
$15.11 /

-0.45 (-2.89%)

RAD Rite Aid
$15.11 /

-0.45 (-2.89%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.